Έμβλημα Κυπριακής Δημοκρατίας

News


Notification of a concentration concerning the acquisition by Medicover Investment B.V. of part of the share capital of NIPD Genetics Public Company Limited
04/01/2022


The Service of the Commission for the Protection of Competition announces that it has received a notification of concentration by Medicover Investment B.V. regarding the acquisition of part of the share capital of NIPD Genetics Public CompanyLimited.

Medicover Investment B.V. is the primary holding company for the Diagnostics Department of the Medicover Group, which is registered in Netherlands.

Medicover Group is a specialized provider of diagnostic and health services, with an emphasis mainly on the markets of Central and Eastern Europe and India. The Group operates through two departments - Diagnostic services and Healthcare Services. Healthcare Services offer high-quality care based on a comprehensive healthcare model, which is offered as assistance and medical insurance to client company employees or individual customers. The portfolio includes services in the areas of prevention, specialised healthcare, hospital care, state-of-the-art dental services and innovative wellness solutions, including sports activities and nutrition. The department is addressed to both corporate and private customers and patients as well as to public payers. Diagnostic Services provide a wide range of laboratory tests in all important areas of clinical pathology, such as allergy diagnostics and auto-immune diseases, bacteriology, parasitology, biochemistry and immunochemistry, blood group diagnostics/transfusion medicine, tumor markers, clinical chemistry, cytology, hematology, histopathology, human genetics, hygiene, immunology and immunochemistry, infectious diseases, microbiology, molecular biology pharmacology/toxicology.

NIPD Genetics Public Company Limited is a public company incorporated in accordance with the laws of the Republic of Cyprus. NIPD is an innovative biotechnology company that designs, develops, produces and provides advanced laboratory tests. NIPD provides genetic services internationally through cap & clia central laboratories. It also provides technology transfer and CE-IVD kits. NIPD also provides research and development (R&D) and customized services to pharmaceutical, industrial and academic companies internationally, as well as clinical laboratory services in Cyprus.







  Twitter Icon  Facebook Icon

Cartel Hotline

Commission Decisions

whistleblowers

e-procurement

GDPR

About Cyprus

Your Europe